logo

For the Inventor, By the Inventor

Harlow, United Kingdom

Andrew Lightfoot

USPTO Granted Patents = 11 


 

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 52(Granted Patents)


Location History:

  • Harlow, GB (2005 - 2014)
  • Middlesex, GB (2015)
  • Ware, GB (2006 - 2016)

Company Filing History:

goldMedal4 out of 2,198 
 
Smithkline Beecham Corporation
 patents
silverMedal4 out of 38 
 
Proximagen Limited
 patents
bronzeMedal2 out of 1,168 
 
Glaxo Group Limited
 patents
4. 1 out of 2 
 
Peptinnovate Limited
 patents

Years Active: 2005-2016

Loading Chart...
Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 9320791 - Peptides from chaperonin 60.1 (2016-04-26),
2. 9133178 - Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease (2015-09-15),
3. 8796283 - Indole and azaindole modulators of the alpha 7 nachr (2014-08-05),
4. 8377941 - Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7 (2013-02-19),
5. 8283365 - Indole modulators of the alpha 7 nicotinic acetylcholine receptor (2012-10-09),
6. 7534793 - Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity (2009-05-19),
7. 7504392 - 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use (2009-03-17),
8. 7429579 - Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) (2008-09-30),
9. 7122538 - Sulfonamide derivatives as antipsychotic agents (2006-10-17),
10. 7001913 - Aminopiperidine derivatives as antibacterials (2006-02-21),
11. 6962917 - Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity (2005-11-08),

Title: Andrew Lightfoot: Innovator in Medical Research

Introduction

Andrew Lightfoot, a prominent inventor based in Harlow, GB, has made significant contributions to the field of medical research through his innovative inventions. With a total of 11 patents to his name, he has focused on developing solutions for various health conditions, showcasing his commitment to advancing medical science.

Latest Patents

Among his latest patents, Lightfoot has introduced innovative peptides derived from chaperonin 60.1, detailing their potential use in treating inflammatory conditions. Additionally, he has patented alpha-7 nicotinic receptor modulators aimed at addressing pain, psychotic disorders, cognitive impairments, and Alzheimer's disease. These compounds are designed to modulate the alpha-7 nicotinic acetylcholine receptor (nAChR), with specific formulas described in the patent documentation.

Career Highlights

Throughout his career, Andrew Lightfoot has collaborated with esteemed organizations such as SmithKline Beecham Corporation and Proximagen Limited. His expertise in medical research and invention has positioned him as a significant contributor to advancements in therapeutic options.

Collaborations

Lightfoot has had the opportunity to work alongside talented colleagues, including David Thomas Davies and Roger Edward Markwell. These collaborations have further enriched his innovative endeavors, fostering an environment of creative problem-solving and scientific inquiry.

Conclusion

Andrew Lightfoot stands out as a remarkable inventor whose work continues to influence the medical research landscape. With his recent patents and collaborative efforts, he exemplifies the spirit of innovation that drives progress in addressing critical health challenges. His contributions are undoubtedly paving the way for new treatment possibilities in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…